




International Journal of Phytochemistry and ChemAnalysis (IJPCA)

Journal Homepage: <https://sennosbiotech.com/IJPCA/1>**Review Article****RP-HPLC Methodology for Olanzapine Impurity Analysis: Advances in Development and Validation****Rutuja Desai*, Pratiksha Dhumal**

Delight College of Pharmacy Koregaon Bhima Tq-Shirur Dist-Pune

ARTICLE INFO

ABSTRACT

Olanzapine, an atypical antipsychotic drug, plays a critical role in the treatment of psychiatric disorders, necessitating the availability of reliable analytical methods for its quantification and quality assessment. Chromatography, particularly reverse-phase high-performance liquid chromatography (RP-HPLC), serves as the cornerstone of separation science in pharmaceutical research and development. This review highlights the development and validation of an RP-HPLC method tailored for olanzapine analysis, emphasizing its significance in drug discovery, development, and manufacturing processes. Validation ensures the method's reliability in determining key characteristics of olanzapine against established acceptance criteria. Parameters such as accuracy, precision, specificity, linearity, range, limits of detection (LOD) and quantification (LOQ), robustness, and system suitability are comprehensively assessed in compliance with ICH guidelines. By offering insights into the critical aspects of method development and validation, this review aims to provide a robust framework for ensuring the quality, efficacy, and safety of olanzapine formulations.

Keywords: RP-HPLC; Olanzapine; Analytical Validation; Impurity Profiling; ICH Guidelines**** Corresponding author****Rutuja Desai***E-mail addresses: rutujad8796@gmail.com , pratikshasdhmal1202@gmail.com

Received date: 06-Sep-2024 Revised date: 22-Sep-2024 Accepted date:15-Oct-2024

DOI: <https://doi.org/10.61920/58jmr165>

1. INTRODUCTION

Olanzapine is a prominent second-generation antipsychotic drug widely prescribed for managing psychiatric disorders such as schizophrenia and bipolar disorder. Due to its broad therapeutic applications and global usage, ensuring the drug's quality, stability, and safety is of paramount importance. Analytical techniques play a pivotal role in monitoring and controlling the quality of pharmaceutical substances, where impurity profiling, stability studies, and method validation are critical for regulatory compliance [1].

Reverse-phase high-performance liquid chromatography (RP-HPLC) has emerged as the method of choice for olanzapine characterization due to its exceptional precision, sensitivity, and ability to handle complex pharmaceutical matrices. This technique has become a cornerstone of separation science in both academic research and industrial applications, offering unparalleled advantages for detecting, quantifying, and analyzing impurities. Impurities, whether arising from synthesis, degradation, or manufacturing processes, can significantly impact drug efficacy and safety. Thus, impurity profiling through validated RP-HPLC methods is vital for ensuring that pharmaceutical products meet regulatory standards and maintain therapeutic integrity [2].

Method development and validation are integral to the drug development process, encompassing every stage from discovery to manufacturing and quality control. According to International Council for Harmonisation (ICH) guidelines, method validation involves the systematic evaluation of parameters such as accuracy, precision, specificity, linearity, range, limit of detection (LOD), limit of quantification (LOQ), robustness, and system

suitability. These parameters ensure that the developed analytical method is both reliable and reproducible under varying conditions [3, 4].

This review article provides a comprehensive analysis of the advancements in RP-HPLC methods for the characterization of olanzapine, with a special focus on impurity profiling and validation strategies. By consolidating recent findings and best practices, this work aims to offer insights into the critical aspects of RP-HPLC method development and its role in supporting regulatory requirements, enhancing quality assurance, and safeguarding public health. Through a detailed examination of current methodologies, challenges, and opportunities, this review underscores the significance of chromatographic advancements in pharmaceutical analysis and their implications for olanzapine characterization.

2. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

High-Performance Liquid Chromatography (HPLC) is a sophisticated analytical technique widely employed for the separation, identification, and quantification of compounds in pharmaceutical formulations. Its ability to analyze complex mixtures with high resolution makes it a cornerstone of modern analytical science. In the context of olanzapine, HPLC is indispensable for impurity profiling, stability testing, and quality control, ensuring compliance with stringent regulatory guidelines [5].

The fundamental components of HPLC include a mobile phase, stationary phase, injector, pump, detector, and data acquisition system. The mobile phase, typically a combination of solvents, carries the analyte through the stationary phase, which is

housed within a chromatographic column. The interaction between the analyte and the stationary phase enables the separation of compounds based on their physicochemical properties, such as polarity or size. The detector measures the separated compounds, providing quantitative and qualitative data[6].

Figure 1 below presents a schematic diagram of a typical HPLC setup, illustrating the flow of the mobile phase, sample injection, separation in the column, and detection. This configuration highlights the efficiency and versatility of HPLC in analyzing pharmaceutical substances.

This analytical tool has become the backbone of impurity profiling in olanzapine, offering precise detection of degradation products, process-related impurities, and other potential contaminants. Additionally, the versatility of HPLC allows for the fine-tuning of parameters such as mobile phase composition, flow rate, and detection wavelength, optimizing method performance for olanzapine analysis. By adhering to International Council for Harmonisation (ICH) guidelines, HPLC methods ensure accuracy, precision, and reliability in assessing olanzapine's quality and safety [7].




Figure 1: Schematic Diagram of High-Performance Liquid Chromatography

2.1 Reverse phase chromatography

Since the 1960s, chromatographers have modified silica with organic silanes to alter its surface properties, transforming the naturally polar silica into a non-polar stationary phase. This modification enables the use of polar solvents for the separation of water-soluble polar molecules. The term "reverse-phase chromatography" describes this

technique, where the polarities of the stationary and mobile phases are reversed compared to traditional normal-phase chromatography [8].

Reversed-phase chromatography is widely utilized due to the availability of numerous chemically bonded stationary phases based on silica. These phases typically contain functional groups covalently attached to the silica surface, enhancing

their stability and separation performance. Additionally, polymer-based absorbents, such as styrene-divinyl benzene copolymers, are gaining traction as alternatives in reversed-phase chromatography.

The retention mechanism in reversed-phase chromatography is influenced by the interactions between solutes and the hydrophobic stationary phase. Retention increases with greater contact between the analyte and the stationary phase, as this interaction is driven by the release of water molecules from the structured water network surrounding the solute. Generally, branched-chain compounds elute faster than their linear isomers due to reduced surface contact. Non-polar solutes interact strongly with the hydrocarbon chains of the stationary phase, while polar or ionic compounds are more soluble in the mobile phase and thus elute faster [9].

In reversed-phase systems, the mobile phase is usually water-based, with organic modifiers like methanol or acetonitrile added to enhance separation. Factors such as pH, temperature, and solvent composition significantly impact chromatographic performance. UV detection is the most commonly employed detection method due to its sensitivity and compatibility with reversed-phase systems.

2.3 Certain Limitations of RP-HPLC

Reversed-phase chromatography, while highly versatile, has some inherent limitations. Polar compounds with significantly different retention properties from the target analyte may co-elute with the solvent front, making their separation challenging. Additionally, analytes with low UV absorption or differing wavelength maxima might

not be detectable at lower concentrations if the detection system monitors only one or two wavelengths. These limitations highlight the importance of optimizing method parameters and considering complementary techniques when necessary [10].

3. METHOD DEVELOPMENT

The development of a robust high-performance liquid chromatography (HPLC) method involves several systematic steps, ensuring precise and accurate analysis of the drug molecule. The process begins with understanding the physicochemical properties of the drug, such as its solubility, polarity, pKa, and stability, as these characteristics influence its behavior in the chromatographic system. Once the properties are established, suitable chromatographic conditions are selected, including the choice of stationary phase (e.g., C18 or C8 columns), mobile phase composition, pH, flow rate, and detection wavelength, to achieve optimal separation and resolution of the analyte [11,12].

After establishing the chromatographic conditions, the approach to analysis is developed, focusing on achieving reproducible retention times and baseline separation of the target compound and its impurities. Sample preparation is a crucial step, involving processes such as filtration, dilution, or extraction, to ensure that the sample is free from particulate matter and compatible with the HPLC system. The method is then optimized by fine-tuning the chromatographic parameters to enhance separation efficiency, peak symmetry, and sensitivity. Finally, the method undergoes validation to confirm its reliability and compliance with regulatory requirements. Validation assesses critical parameters, including accuracy, precision, linearity,

specificity, robustness, limit of detection (LOD), and limit of quantification (LOQ), ensuring the method is fit for its intended purpose. This structured approach to method development is

essential for producing consistent and reproducible results, particularly in pharmaceutical quality control and regulatory compliance [13].




Figure 2: Steps involved in HPLC method validation

3.1 Significance of Physicochemical Properties in Method Development

A detailed understanding of the physicochemical properties of a drug molecule is fundamental to the development of an effective HPLC method. These attributes, such as solubility, polarity, pKa, molecular weight, and stability, significantly influence the choice of chromatographic parameters and the overall performance of the analytical method. Solubility determines the compatibility of the drug with mobile phase solvents, ensuring consistent analyte behavior during separation. Polarity guides the selection of stationary phases, particularly in reversed-phase chromatography, where non-polar columns are commonly used to

separate compounds based on hydrophobic interactions [14].

The pKa value of the drug dictates the optimal pH of the mobile phase, as maintaining the analyte in its desired ionic or non-ionic state ensures better retention and peak resolution. Additionally, the stability of the drug under various conditions—such as exposure to light, temperature, or solvents—is essential to avoid degradation during sample preparation or analysis. By thoroughly evaluating these properties, the foundation is set for selecting appropriate chromatographic conditions, facilitating method optimization, and achieving accurate, precise, and reproducible results. This understanding is critical for ensuring method

robustness and compliance with regulatory standards in pharmaceutical analysis [15].

3.2 Selection of chromatographic conditions

The selection of chromatographic conditions is a critical step in the development of an HPLC method, as it directly influences the efficiency and accuracy of the separation. Several factors must be considered to achieve optimal resolution, peak symmetry, and sensitivity for the analyte of interest. The first consideration is the choice of stationary phase, with reversed-phase columns (such as C18 or C8) being most commonly used for pharmaceutical applications due to their non-polar nature, which interacts effectively with hydrophobic compounds like olanzapine [16].

Next, the mobile phase composition is carefully chosen based on the polarity and solubility of the drug molecule. Typically, a combination of water and organic solvents like methanol, acetonitrile, or isopropanol is used to create a gradient or isocratic elution system. The pH of the mobile phase is another important factor, as it can influence the ionization state of the drug and, consequently, its retention time. The pH should be optimized to ensure the analyte remains in its most stable and ionized form for effective separation.

Flow rate is another parameter that must be optimized to balance resolution and analysis time. A higher flow rate can reduce analysis time but may compromise resolution, while a slower flow rate may improve separation but increase run times. Detection wavelength is selected based on the absorbance properties of the drug molecule, with UV detection being most common for olanzapine, due to its chromophore properties.

Overall, selecting the appropriate chromatographic conditions involves balancing these factors to ensure the drug and its impurities are effectively separated with high precision, sensitivity, and reproducibility. The conditions must also be compatible with the equipment and capable of yielding results that meet regulatory and quality standards [17].

4. DEVELOPING THE APPROACH FOR ANALYSIS

Developing the approach for analysis is a pivotal step in HPLC method development, where the overall strategy for separation, identification, and quantification of the drug molecule is established. This stage involves defining the specific goals of the analysis, such as determining the purity of the drug, quantifying the drug concentration, or profiling impurities. The approach is carefully designed to ensure that the method will effectively address these objectives while maintaining reproducibility and accuracy across multiple samples and conditions.

One key aspect is the selection of the type of analysis to be performed—whether it will be qualitative or quantitative. For qualitative analysis, the primary goal is to identify the presence of specific impurities or degradation products, whereas quantitative analysis focuses on accurately determining the drug's concentration in a sample. The approach must also consider the potential complexity of the matrix in which the drug is present, as the method needs to distinguish the drug from excipients, impurities, and degradation products [18].

The chromatographic parameters developed in the previous step are refined further to ensure they align with the goals of the analysis. For instance, if the aim is to identify impurities, the approach may involve adjusting the mobile phase or detection wavelength

to enhance sensitivity for low-concentration components. Alternatively, if the goal is to quantify the drug accurately, the approach will focus on optimizing the resolution and precision of the main peak while ensuring minimal interference from neighboring peaks [19].

Developing a robust approach also includes considering potential challenges, such as overlapping peaks, matrix effects, or degradation products. It is essential to establish a protocol for handling these challenges, such as employing sample clean-up techniques or using different detection methods, to ensure that the method remains effective and reliable. By setting clear objectives and designing the analysis with precision, this step ensures that the final HPLC method will meet the analytical needs and comply with regulatory guidelines [20].

5. SAMPLE PREPARATION

Sample preparation is a crucial step in HPLC analysis, ensuring that the drug sample is properly prepared for injection into the chromatographic system. This process typically involves steps such as filtration, dilution, and, if necessary, extraction to remove particulate matter, impurities, or interfering substances. The sample must be dissolved in an appropriate solvent that is compatible with the mobile phase and does not cause precipitation or degradation of the analyte. Proper sample preparation ensures that the analyte is in a suitable concentration range for detection and that the results are reliable, accurate, and reproducible. Careful handling of the sample also prevents contamination and loss of the analyte, optimizing the efficiency and precision of the analysis [21].

6. METHOD OPTIMIZATION

Method optimization in HPLC is the process of fine-tuning chromatographic conditions to achieve the best possible separation, resolution, and sensitivity for the analyte. This step involves adjusting key parameters such as mobile phase composition, pH, flow rate, column temperature, and detection wavelength to enhance the performance of the method. The goal is to minimize analysis time while ensuring accurate and reproducible results, without compromising the separation of the target compound and its impurities.

Optimization often includes adjusting the mobile phase gradient or flow rate to improve the peak shape and resolution between closely eluting compounds. The pH of the mobile phase may also be modified to maintain the drug molecule in its most stable and ionized form, improving both retention and separation. Temperature control of the column can be used to increase resolution, especially for thermally stable compounds. In addition, the sensitivity of detection methods (such as UV or fluorescence detection) is optimized by selecting the most appropriate wavelengths or settings for the analyte and potential impurities. Through systematic optimization, the method is refined to provide consistent, high-quality results while meeting the specific needs of the analysis [22].

7. METHOD VALIDATION

Method validation is the final and most critical step in the development of an HPLC method, ensuring that the method performs as intended and meets the required regulatory standards. It involves a series of systematic tests to assess the method's reliability, accuracy, and reproducibility under various conditions. Validation parameters are based on guidelines from organizations such as the

International Council for Harmonisation (ICH), which outlines the key characteristics to be evaluated [23].

Key parameters for validation include:

- **Accuracy:** The degree to which the method gives results close to the true value, usually assessed through recovery studies.
- **Precision:** The method's ability to provide consistent results when repeated under the same conditions, often evaluated through repeatability and intermediate precision tests.
- **Specificity:** The method's ability to measure the analyte without interference from other substances, such as excipients or impurities.
- **Linearity:** The method's ability to generate results that are directly proportional to the concentration of the analyte over a specified range.
- **Range:** The concentration limits within which the method is applicable.
- **Limit of Detection (LOD) and Limit of Quantification (LOQ):** The lowest amount of the analyte that can be reliably detected and quantified.
- **Robustness:** The ability of the method to remain unaffected by small variations in experimental conditions, ensuring the method's reliability under different operating conditions.
- **System Suitability:** The performance of the system under typical conditions to ensure that it is functioning properly, including column efficiency, resolution, and sensitivity.

Successful validation confirms that the HPLC method is reliable, reproducible, and fit for its intended purpose, providing high-quality results that comply with regulatory requirements for pharmaceutical testing [24].

8. METHOD DEVELOPMENT AND VALIDATION BY RP-HPLC METHOD FOR OLANZAPINE

Various researchers have developed and validated HPLC methods for the estimation of olanzapine in pharmaceutical formulations, with each study aiming to provide accurate, reliable, and efficient analysis. Jain et al. designed a stability-indicating RP-HPLC method that was simple, precise, and quick. Using a C-18 column and a mobile phase consisting of potassium dihydrogen phosphate buffer (pH 6) and acetonitrile (60:40 v/v), the method provided accurate results for olanzapine in the concentration range of 5-25 µg/mL, with an excellent linearity (correlation coefficient of 0.998). Recovery studies confirmed the method's reliability, and robustness tests showed that the method remained effective under varying conditions such as changes in temperature, flow rate, and mobile phase ratio.

In another study by Prameela Rani et al., a reverse-phase HPLC method was developed for olanzapine determination in tablets. The method, which used an Inertsil C18 column and a mobile phase of ammonium phosphate buffer and methanol, showed a linear response in the concentration range of 2–10 µg/mL, with a retention time of 3.447 minutes. This method proved useful for determining olanzapine content in pharmaceutical formulations.

Kanakapura Basavaiah et al. also contributed to the development of an HPLC method for olanzapine,

using a reversed-phase Intersil ODS column. The analysis was completed in less than 10 minutes, with a flow rate of 0.5 mL/min and UV detection at 271 nm. The method exhibited a linear range of 10-200 µg/mL, and the detection and quantification limits were found to be 3.0 µg/mL and 8.0 µg/mL, respectively. The method was validated according to ICH guidelines for accuracy, precision, and robustness [25].

Finally, Basavaiah et al. and Baldanla et al. developed a simple, accurate, and specific reverse-phase liquid chromatographic method for olanzapine quantification in tablets. Their method used acetonitrile, methanol, and potassium dihydrogen orthophosphate as the mobile phase, and it was validated for parameters like linearity, precision, and stability. The method showed excellent recovery rates (99.02%-101.68%) and was able to determine olanzapine in tablet formulations with high accuracy. These studies highlight the versatility and reliability of RP-HPLC for the analysis of olanzapine in different pharmaceutical contexts [26,27].

CONCLUSION

This review highlights the development and validation of RP-HPLC methods for the analysis of olanzapine, emphasizing the importance of both processes in ensuring accurate measurements and reliable performance. The selection of chromatographic conditions, such as column type, buffer composition, detector settings, and wavelength, plays a crucial role in achieving optimal separation and selectivity. The RP-HPLC method offers numerous advantages, including high selectivity, sensitivity, cost-effectiveness, minimal analysis time, and low detection limits. The method

can be further optimized by adjusting factors such as gradient slope, temperature, flow rate, and mobile phase modifiers. Following ICH guidelines, the developed RP-HPLC techniques are validated for key parameters, including specificity, precision, accuracy, detection limits, and linearity, ensuring their suitability for routine pharmaceutical analysis of olanzapine.

ACKNOWLEDGMENT

We would like to thank the Department of Pharmaceutics, Delight College of Pharmacy Koregaon Bhima Tq-shirur Dist-Pune forgives guidance and support for conducting a research study.

DECLARATION OF COMPETING INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

FUNDING

Not Applicable

AUTHORSHIP CONTRIBUTION STATEMENT

Rutuja Desai: Supervision, Validation, Methodology, Investigation, Writing – original draft, **Pratiksha Dhumal:** Conceptualization, Administration, Funding, Data Curation.

REFERENCES

1. Çöpür S, Çöpür M. Olanzapine in the treatment of anorexia nervosa: a systematic review. Egypt J Neurol Psychiatry Neurosurg. 2020 Dec 1;56(1).
2. B F, KL G. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of

- schizophrenia and related psychoses. *Drugs* [Internet]. 1997 [cited 2021 Aug 28];53(2):281–98. Available from: <https://pubmed.ncbi.nlm.nih.gov/9028746/>
3. Hocking CM, Kichenadasse G. Olanzapine for chemotherapy-induced nausea and vomiting: A systematic review. *Support Care Cancer*. 2014;22(4):1143–51.
 4. San L, Casillas M, Ciudad A, Gilaberte I. Olanzapine orally disintegrating tablet: A review of efficacy and compliance. *CNS Neurosci Ther*. 2008 Sep;14(3):203–14.
 5. Meftah AM, Deckler E, Citrome L, Kantrowitz JT. New discoveries for an old drug: a review of recent olanzapine research. *Postgrad Med*. 2020 Jan 2;132(1):80–90.
 6. Sahu P, Ramisetty N, Cecchi T, ... SS-... of pharmaceutical and, 2018 undefined. An overview of experimental designs in HPLC method development and validation. Elsevier [Internet]. 2018 [cited 2021 Aug 28];147:590–611. Available from: <https://www.sciencedirect.com/science/article/pii/S0731708517303746>
 7. Sabir AM, Moloy M, Bhasin PS. Hplc Method Development and Validation: a Review. *Int Res J Pharm*. 2016;4(4):39–46.
 8. Kumar A, Jawla S, Yadav G. Recent analytical method developed by RP-HPLC. *Glob J Pharmacol*. 2013;7(3):232–40.
 9. Sangeetha M, Reichal CR, Indulatha V, Thirumoorthy N. Development and Validation of RP-HPLC Method: An Overview. *Res Rev J of Pharmaceutical Anal* [Internet]. [cited 2021 Aug 28];3(4):8–14. Available from: <https://www.rroij.com/open-access/development-and-validation-of-rphplc-method-an-overview-.php?aid=34720>
 10. Pervaiz F, Ahmad M, Minhas MU, Sohail M. Development and validation of reverse phase high performance chromatography method for determination of olanzapine in microsample rat plasma: Application to preclinical pharmacokinetic study. *Trop J Pharm Res*. 2015;14(1):141–7.
 11. L.R.D.Bhavani, R D aruna. Method Development and Validation Parameters of HPLC- A Mini Review. *Res Rev J Pharm Anal* [Internet]. 2015 Jun 2 [cited 2021 Aug 31];4(2). Available from: <https://www.rroij.com/open-access/method-development-and-validation-parameters-of-hplc-a-mini-review.php?aid=52929>
 12. Kiran Kumar K, Venkata Nadh R. Development and validation of HPLC method for the estimation of nicergoline in marketed formulations. *Rasayan J Chem*. 2011;4(4):885–9.
 13. Swetha Reddy G. A Review on new Analytical method Development and Validation by RP-HPLC. A Rev new Anal method Dev Int Res J Pharm Biosci [Internet]. 2017 [cited 2021 Aug 28];4(3). Available from: <http://www.irjpbs.com>
 14. Bhatt R, Singh G, Tiwari A, Jain NK. RP-HPLC Method Development, Validation and Stability Indicating Study of Olanzapine

- in Tablet Dosage Form. 2020 [cited 2021 Aug 30];11(11):7079–84. Available from: www.ijplsjournal.com
15. Papadoyannis IN, Samanidou VF. Validation of HPLC Instrumentation. *J Liq Chromatogr Relat Technol.* 2004 Jan;27(5):753–83.
 16. Soman A, Qiu Y, chromatographic QCL-J of, 2008 undefined. HPLC-UV method development and validation for the determination of low level formaldehyde in a drug substance. *academic.oup.com* [Internet]. [cited 2021 Aug 31]; Available from: <https://academic.oup.com/chromsci/article-abstract/46/6/461/314726>
 17. Sudev S, Janardhanan.V S. Review Article Review on HPLC Method Development Validation and Optimization 1. *Int J Pharm Sci Rev Res* Available. 2019;56(05):28–43.
 18. Cui D, Li Y, Lian M, Yang F, Meng Q. Development of a simple and stability-indicating RP-HPLC method for determining olanzapine and related impurities generated in the preparative process. *Analyst* [Internet]. 2011 Jul 11 [cited 2021 Aug 28];136(15):3149–56. Available from: <https://pubs.rsc.org/en/content/articlehtml/2011/an/c1an15155j>
 19. Murugan S, Elayaraja A, ... KC-I journal of, 2013 undefined. A Review on Method Development and Validation by Using HPLC. *CiteSeer* [Internet]. [cited 2021 Aug 31]; Available from: <http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1075.4743&rep=rep1&type=pdf>
 20. Dadhich B, Goyal R, Agarwal D. A Review On: Development and Validation of HPLC in Pharmaceutical Dosage Form. *Asian J Pharm Res Dev* [Internet]. 2020 Aug 15 [cited 2021 Aug 28];8(4):110–21. Available from: <https://ajprd.com/index.php/journal/article/view/656>
 21. Research RS-J of PE&, 2013 undefined. HPLC method development and validation-an overview. *search.ebscohost.com* [Internet]. [cited 2021 Aug 31]; Available from: <http://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authType=crawler&jrnl=09768173&AN=88925378&h=r0ksd9B%2FD%2FqwCrrdyZqgiBvW3yv%2FIQh432%2FkYE3I%2FkWbiPXMQbNNuWlh%2B%2ByhX35naRkWYNzfFVvNLv90XLSHFA%3D%3D&crl=c>
 22. Al-nimry SS, Khanfar MS. Validation of an rp-hplc method for the determination of asenapine maleate in dissolution media and application to study in vitro release from co-crystals. *Sci Pharm.* 2021;89(1).
 23. Satyanarayana P, Karthik Varma K, Sudarshan Reddy P, Nagaraju TM, Roosewelt C. Development of HPLC method for the determination of zinc carnosine in Bulk and dosage forms. *Int J ChemTech Res.* 2012;4(2):842–6.
 24. Sahu P, Ramiseti N, Cecchi T, ... SS-... of pharmaceutical and, 2018 undefined. An overview of experimental designs in HPLC

- method development and validation. Elsevier [Internet]. [cited 2021 Aug 31]; Available from: <https://www.sciencedirect.com/science/article/pii/S0731708517303746>
25. Jain N, Joshi A, Vyas N, Malviya S, Kharia A. DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF OLANZAPINE IN MARKETED FORMULATION. J Drug Deliv Ther [Internet]. 2017 Dec 22 [cited 2021 Aug 28];7(7):121–2. Available from: <http://jddtonline.info/index.php/jddt/article/view/1607>
26. (PDF) Development of HPLC method for the determination of olanzapine in bulk and dosage forms [Internet]. [cited 2021 Aug 28]. Available from: https://www.researchgate.net/publication/238727092_Development_of_HPLC_method_for_the_determination_of_olanzapine_in_bulk_and_dosage_forms
27. Baldanla SL, Bhatt KK, Mehta RS, Shah DA, Gandhi TR. Development and validation of RP-HPLC method for the estimation of olanzapine in pharmaceutical dosage forms. Indian Drugs. 2008;45(6):493–8.